| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Departments of Pathology* and Internal Medicine, Seoul National University College of Medicine, Seoul; and the Cancer Research Institute, Seoul, Korea
To determine the methylation profile of multiple tumor-related genes during multistep hepatocarcinogenesis, we investigated the methylation status of CpG islands of 9 genes, using methylation-specific polymerase chain reaction for 60 paired hepatocellular carcinoma (HCC) and non-HCC liver tissue samples, 22 dysplastic nodule (DN), 30 liver cirrhosis (LC), 34 chronic hepatitis (CH) and 20 normal liver samples. The methylation status of 9 genes was correlated to the clinicopathological findings of HCC patients. All HCC samples showed methylation of at least one gene, whereas it was shown in 72.7% of DN and 40% of LC, but was not shown in CH and normal liver samples (P < 0.001). The number of genes methylated showed a stepwise increase with the progression of stages (0 for normal liver and CH, 0.5 for LC, 1.5 for DN, and 3.7 for HCC (P < 0.001)). The genes frequently methylated in HCC were APC (81.7%), GSTP1 (76.7%), RASSF1A (66.7%), p16 (48.3%), COX-2 (35%), and E-cadherin (33.3%). COX-2, p16, RASSF1A, and TIMP-3 were not methylated in LC and CH from patients without concurrent HCC. Chronic liver diseases with concurrent HCC showed higher methylation frequencies of the tested genes, and a higher number of methylated genes than those without concurrent HCC. HCC patients with methylation of E-cadherin or GSTP1 showed poorer survival than those without (P = 0.034 and 0.043, respectively). In conclusion, our results indicated that CpG island methylation of tumor-related genes is an early and frequent event, and accumulates step-by-step during a multistep hepatocarcinogenesis. CpG island methylation of E-cadherin or GSTP1 might serve as a potential biomarker for prognostication of HCC patients.
This article has been cited by other articles:
 |
|
 |
|
  J. K. Jung, P. Arora, J. S. Pagano, and K. L. Jang Expression of DNA Methyltransferase 1 Is Activated by Hepatitis B Virus X Protein via a Regulatory Circuit Involving the p16INK4a-Cyclin D1-CDK 4/6-pRb-E2F1 Pathway Cancer Res., June 15, 2007; 67(12): 5771 - 5778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Lehmann, L. U. Wingen, K. Brakensiek, H. Wedemeyer, T. Becker, A. Heim, K. Metzig, B. Hasemeier, H. Kreipe, and P. Flemming Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis Hum. Mol. Genet., June 1, 2007; 16(11): 1335 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nishida, T. Nishimura, T. Nagasaka, I. Ikai, G. Ajay, and C. R. Boland Extensive Methylation Is Associated with {beta}-Catenin Mutations in Hepatocellular Carcinoma: Evidence for Two Distinct Pathways of Human Hepatocarcinogenesis Cancer Res., May 15, 2007; 67(10): 4586 - 4594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zhang, Z. Li, Y. Cheng, F. Jia, R. Li, M. Wu, K. Li, and L. Wei CpG Island Methylator Phenotype Association with Elevated Serum {alpha}-Fetoprotein Level in Hepatocellular Carcinoma Clin. Cancer Res., February 1, 2007; 13(3): 944 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gu, D. Berman, C. Lu, I. I. Wistuba, J. A. Roth, M. Frazier, M. R. Spitz, and X. Wu Aberrant Promoter Methylation Profile and Association with Survival in Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7329 - 7338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yuan, J. Wang, J. Li, L. Wang, M. Li, Z. Yang, C. Zhang, and J. L. Dai Frequent Epigenetic Inactivation of Spleen Tyrosine Kinase Gene in Human Hepatocellular Carcinoma. Clin. Cancer Res., November 15, 2006; 12(22): 6687 - 6695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Katoh, T. Shibata, A. Kokubu, H. Ojima, M. Fukayama, Y. Kanai, and S. Hirohashi Epigenetic Instability and Chromosomal Instability in Hepatocellular Carcinoma Am. J. Pathol., April 1, 2006; 168(4): 1375 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. van der Weyden, K. K. Tachibana, M. A. Gonzalez, D. J. Adams, B. L. Ng, R. Petty, A. R. Venkitaraman, M. J. Arends, and A. Bradley The RASSF1A Isoform of RASSF1 Promotes Microtubule Stability and Suppresses Tumorigenesis Mol. Cell. Biol., September 15, 2005; 25(18): 8356 - 8367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Hoque, E. Rosenbaum, W. H. Westra, M. Xing, P. Ladenson, M. A. Zeiger, D. Sidransky, and C. B. Umbricht Quantitative Assessment of Promoter Methylation Profiles in Thyroid Neoplasms J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4011 - 4018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Lehmann, I. Berg-Ribbe, L. U. Wingen, K. Brakensiek, T. Becker, J. Klempnauer, B. Schlegelberger, H. Kreipe, and P. Flemming Distinct Methylation Patterns of Benign and Malignant Liver Tumors Revealed by Quantitative Methylation Profiling Clin. Cancer Res., May 15, 2005; 11(10): 3654 - 3660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cerimele, T. Battle, R. Lynch, D. A. Frank, E. Murad, C. Cohen, N. Macaron, J. Sixbey, K. Smith, R. S. Watnick, et al. Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma PNAS, January 4, 2005; 102(1): 175 - 179. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
